Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 491-501

  Freedman, Rachel A ^a   Vaz Luis, Ines ^a,b   Barry, William T ^a   Lii, Huichuan ^c   Lin, Nancy U ^a   Winer, Eric P ^a   Keating, Nancy L ^c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Non standard chemotherapy; Older women; Outcomes; Toxicity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; ASTHMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; DEEP VEIN THROMBOSIS; DEHYDRATION; DELIRIUM; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HIP FRACTURE; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALNUTRITION; MEDICARE; MENTAL DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; SHORT TERM SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; MORTALITY; SURVIVAL RATE; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FEMALE; HUMANS; MEDICARE; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84901692250     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2968-9     Document Type: Article

References (39)

1. Cho HS, Mason K, Ramyar KX et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760 (Pubitemid 36227628)
2. Yarden Y (2001) The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3-S8
3. Clarke CA, Keegan TH, Yang J et al (2012) Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 104:1094-1101
4. Laird-Fick H, Gardiner J, Tokala H et al (2013) HER2 status in elderly women with breast cancer. J Geriatr Oncol 4:362-367
5. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684 (Pubitemid 41464706)
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672 (Pubitemid 41464705)
7. Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373
8. National Comprehensive Cancer Network (2013) Clinical practice guidelines in oncology. Breast Cancer V.3.2013 http://www.nccn.org/professionals/ physician-gls/pdf/breast.pdf. Accessed 10 Oct 2013
9. Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839-846
10. Vaz-Luis I, Keating NL, Lin NU et al (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: A population-based study. J Clin Oncol 32:927-934
11. Griggs JJ, Culakova E, Sorbero ME et al (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:2522-2527 (Pubitemid 47041224)
12. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) SEER cancer statistics review, 1975-2008, National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975- 2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011
13. SEER-Medicare: how the SEER & Medicare data are linked. http://healthservices.cancer.gov/seermedicare/overview/linked.html. Accessed 20 Oct 2009
14. Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-IV-18
15. Hassett MJ, O'Malley AJ, Pakes JR et al (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117 (Pubitemid 44288785)
16. Du XL, Osborne C, Goodwin JS (2002) Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642 (Pubitemid 36025279)
17. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267 (Pubitemid 32007842)
18. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251 (Pubitemid 24361532)
19. Hirano K, Imbens G (2001) Estimation of causal effects using propensity score weighting: An application to data on right heart catheterization. Health Serv Outcomes Res Method 2:259-278
20. Rosenbaum P, Rubin D (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516-524
21. Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763 (Pubitemid 27446562)
22. Joffe MM, Ten Have TR, Feldman HI, Kimmel SE (2004) Model selection, confounder control, and marginal structural models: review and new applications. Am Statistician 58:272-279 (Pubitemid 39525979)
23. Lin DY, Psaty BM, Kronmal RA (1998) Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948-963 (Pubitemid 28429289)
24. Lamont EB, Landrum MB, Keating NL et al (2010) Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol 28:215-221
25. Lamont EB, Hayreh D, Pickett KE et al (2003) Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst 95:1370-1375 (Pubitemid 37220456)
26. Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081 (Pubitemid 40300281)
27. Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B experience. J Clin Oncol 25:3699-3704 (Pubitemid 47372610)
28. Bouchardy C, Rapiti E, Fioretta G et al (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21:3580-3587 (Pubitemid 46594049)
29. Hebert-Croteau N, Brisson J, Latreille J et al (1999) Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 85:1104-1113 (Pubitemid 29115590)
30. Elkin EB, Hurria A, Mitra N et al (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: Assessing outcome in a population-based, observational cohort. J Clin Oncol 24:2757-2764 (Pubitemid 46630573)
31. Giordano SH, Duan Z, Kuo YF et al (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750-2756 (Pubitemid 46630572)
32. Yancik R, Wesley MN, Ries LA et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892 (Pubitemid 32171549)
33. Leyland-Jones B, Gelmon K, Ayoub JP et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971 (Pubitemid 46606210)
34. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
35. Tolaney SM, Barry WT, Dang CT et al (2013) A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT Trial) for node-negative, HER2-positive breast cancer (BC). Presented at the San Antonio Breast Cancer Symposium on 12 Dec 2013, Abstract #974
36. Warren JL, Harlan LC, Fahey A et al (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:55-61
37. Bikov KA, Mullins CD, Seal B et al (2013) Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare. Med Care. epub ahead of print
38. Lund JL, Sturmer T, Harlan LC et al (2013) Identifying specific chemotherapeutic agents in Medicare data: A validation study. Med Care 51:e27-e34
39. Burstein HJ, Piccart-Gebhart MJ, Perez EA et al (2012) Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 30:2179-2182